

# **Pulmonary Drugs Market Size, Trends, Analysis, and Outlook By Drug Class (Beta-2 Agonists, Anti-cholinergic Agents, Oral and Inhaled Corticosteroids, Anti-leukotrienes, Antihistamines, Monoclonal Antibodies, Combination Drugs, Others), By Indication (Asthma, COPD (Chronic Obstructive Pulmonary Disease), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), by Country, Segment, and Companies, 2024-2032**

<https://marketpublishers.com/r/P18E3EB7370AEN.html>

Date: April 2024

Pages: 205

Price: US\$ 3,980.00 (Single User License)

ID: P18E3EB7370AEN

## **Abstracts**

The global Pulmonary Drugs market size is poised to register 6.9% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Pulmonary Drugs market across By Drug Class (Beta-2 Agonists, Anti-cholinergic Agents, Oral and Inhaled Corticosteroids, Anti-leukotrienes, Antihistamines, Monoclonal Antibodies, Combination Drugs, Others), By Indication (Asthma, COPD (Chronic Obstructive Pulmonary Disease), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

The pulmonary drugs market is influenced by the increasing prevalence of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension, driven by factors such as urbanization, air pollution, and aging populations. With a growing emphasis on targeted therapies and personalized

medicine, there's a shift towards the development of novel inhalation formulations, biologics, and gene therapies to address unmet needs in respiratory care. By 2030, the market is expected to witness the commercialization of advanced drug delivery devices, innovative treatment modalities, and combination therapies, offering improved symptom control, disease management, and quality of life for patients with pulmonary disorders.

## Pulmonary Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Pulmonary Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Pulmonary Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Pulmonary Drugs industry.

## Key market trends defining the global Pulmonary Drugs demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

## Pulmonary Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2032

The Pulmonary Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Pulmonary Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

## Key strategies adopted by companies within the Pulmonary Drugs industry

Leading Pulmonary Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging

demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Pulmonary Drugs companies.

### Pulmonary Drugs Market Study- Strategic Analysis Review

The Pulmonary Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

### Pulmonary Drugs Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Pulmonary Drugs industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.

### Pulmonary Drugs Country Analysis and Revenue Outlook to 2032

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.

### North America Pulmonary Drugs Market Size Outlook- Companies plan for focused

investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to \$4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Pulmonary Drugs market segments. Similarly, Strong market demand is encouraging Canadian Pulmonary Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Pulmonary Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Pulmonary Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Pulmonary Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Pulmonary Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Pulmonary Drugs Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Pulmonary Drugs in Asia Pacific. In particular, China, India, and South East Asian Pulmonary Drugs markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.

Latin America Pulmonary Drugs Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Pulmonary Drugs Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Pulmonary Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Pulmonary Drugs.

Pulmonary Drugs Market Company Profiles

The global Pulmonary Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AstraZeneca PLC, Boehringer Ingelheim International GmbH, Circassia Pharmaceuticals plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Grifols S.A., Merck & Co. Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi SA, Sumitomo Dainippon Pharma Co. Ltd, Teva Pharmaceutical Industries Ltd.

Recent Pulmonary Drugs Market Developments

The global Pulmonary Drugs market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Pulmonary Drugs Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

## Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

## Market Segmentation:

By Drug Class

Beta-2 Agonists

Anti-cholinergic Agents

Oral and Inhaled Corticosteroids

Anti-leukotrienes

Antihistamines

Monoclonal Antibodies

Combination Drugs

Others

By Indication

Asthma

COPD (Chronic Obstructive Pulmonary Disease)

Allergic Rhinitis

Pulmonary Arterial Hypertension

Cystic Fibrosis

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

## Companies

AstraZeneca PLC

Boehringer Ingelheim International GmbH

Circassia Pharmaceuticals plc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline PLC

Grifols S.A.

Merck & Co. Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Sanofi SA

Sumitomo Dainippon Pharma Co. Ltd

Teva Pharmaceutical Industries Ltd

Formats Available: Excel, PDF, and PPT



## Contents

### 1. EXECUTIVE SUMMARY

- 1.1 Pulmonary Drugs Market Overview and Key Findings, 2024
- 1.2 Pulmonary Drugs Market Size and Growth Outlook, 2021- 2030
- 1.3 Pulmonary Drugs Market Growth Opportunities to 2030
- 1.4 Key Pulmonary Drugs Market Trends and Challenges
  - 1.4.1 Pulmonary Drugs Market Drivers and Trends
  - 1.4.2 Pulmonary Drugs Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Pulmonary Drugs Companies

### 2. PULMONARY DRUGS MARKET SIZE OUTLOOK TO 2030

- 2.1 Pulmonary Drugs Market Size Outlook, USD Million, 2021- 2030
- 2.2 Pulmonary Drugs Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### 3. PULMONARY DRUGS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### 4. PULMONARY DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
  - By Drug Class
    - Beta-2 Agonists
    - Anti-cholinergic Agents
    - Oral and Inhaled Corticosteroids

Anti-leukotrienes  
Antihistamines  
Monoclonal Antibodies  
Combination Drugs  
Others  
By Indication  
Asthma  
COPD (Chronic Obstructive Pulmonary Disease)  
Allergic Rhinitis  
Pulmonary Arterial Hypertension  
Cystic Fibrosis  
Others  
By Distribution Channel  
Hospital Pharmacies  
Retail Pharmacies  
Others  
4.3 Growth Prospects and Niche Opportunities, 2023- 2030  
4.4 Regional comparison of Market Growth, CAGR, 2023-2030

## **5. REGION-WISE MARKET OUTLOOK TO 2030**

5.1 Key Findings for Asia Pacific Pulmonary Drugs Market, 2025  
5.2 Asia Pacific Pulmonary Drugs Market Size Outlook by Type, 2021- 2030  
5.3 Asia Pacific Pulmonary Drugs Market Size Outlook by Application, 2021- 2030  
5.4 Key Findings for Europe Pulmonary Drugs Market, 2025  
5.5 Europe Pulmonary Drugs Market Size Outlook by Type, 2021- 2030  
5.6 Europe Pulmonary Drugs Market Size Outlook by Application, 2021- 2030  
5.7 Key Findings for North America Pulmonary Drugs Market, 2025  
5.8 North America Pulmonary Drugs Market Size Outlook by Type, 2021- 2030  
5.9 North America Pulmonary Drugs Market Size Outlook by Application, 2021- 2030  
5.10 Key Findings for South America Pulmonary Drugs Market, 2025  
5.11 South America Pacific Pulmonary Drugs Market Size Outlook by Type, 2021- 2030  
5.12 South America Pulmonary Drugs Market Size Outlook by Application, 2021- 2030  
5.13 Key Findings for Middle East and Africa Pulmonary Drugs Market, 2025  
5.14 Middle East Africa Pulmonary Drugs Market Size Outlook by Type, 2021- 2030  
5.15 Middle East Africa Pulmonary Drugs Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

- 6.1 US Pulmonary Drugs Market Size Outlook and Revenue Growth Forecasts
- 6.2 US Pulmonary Drugs Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Pulmonary Drugs Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Pulmonary Drugs Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Pulmonary Drugs Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Pulmonary Drugs Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Pulmonary Drugs Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Pulmonary Drugs Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Pulmonary Drugs Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Pulmonary Drugs Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Pulmonary Drugs Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Pulmonary Drugs Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Pulmonary Drugs Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Pulmonary Drugs Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Pulmonary Drugs Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Pulmonary Drugs Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Pulmonary Drugs Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Pulmonary Drugs Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Pulmonary Drugs Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Pulmonary Drugs Industry Drivers and Opportunities

- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Pulmonary Drugs Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Pulmonary Drugs Industry Drivers and Opportunities

## **7. PULMONARY DRUGS MARKET OUTLOOK ACROSS SCENARIOS**

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

## **8. PULMONARY DRUGS COMPANY PROFILES**

- 8.1 Profiles of Leading Pulmonary Drugs Companies in the Market
- 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
- 8.3 Financial Performance and Key Metrics

AstraZeneca PLC

Boehringer Ingelheim International GmbH

Circassia Pharmaceuticals plc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline PLC

Grifols S.A.

Merck & Co. Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Sanofi SA

Sumitomo Dainippon Pharma Co. Ltd

Teva Pharmaceutical Industries Ltd.

## **9. APPENDIX**

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information

## I would like to order

Product name: Pulmonary Drugs Market Size, Trends, Analysis, and Outlook By Drug Class (Beta-2 Agonists, Anti-cholinergic Agents, Oral and Inhaled Corticosteroids, Anti-leukotrienes, Antihistamines, Monoclonal Antibodies, Combination Drugs, Others), By Indication (Asthma, COPD (Chronic Obstructive Pulmonary Disease), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), by Country, Segment, and Companies, 2024-2032

Product link: <https://marketpublishers.com/r/P18E3EB7370AEN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P18E3EB7370AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970